![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, June 22, 2021 10:46:07 AM
Director
Informative Buy
$50,521.00
a month ago
R Hector Mackay-Dunn
Director
Informative Buy
$50,529.00
a month ago
Leversage Jill
Director
Informative Buy
$27,375.00
a month ago
Matthew Maxwell Donley
Ex VP, Intern'l Operations
Informative Buy
$99,693.00
a month ago
Peter Greenleaf
Chief Executive Officer, Director
Informative Buy
$54,891.07
a month ago
Martin Michael Robert
Chief Business Officer
Informative Buy
$60,400.00
a month ago
Max Donley
Executive Vice-President - Operations
Informative Buy
$99,738.54
a month ago
Jill Diane Leversage
Director
Informative Buy
$27,389.25
a month ago
Peter Greenleaf
Chief Executive Officer
Informative Buy
$54,891.31
a month ago
Michael Robert Martin
Divisional Vice-President
Uninformative Sell
$60,400.00
a month ago
Robert Huizinga
Divisional Executive Vice-President
Uninformative Sell
$120,800.00
a month ago
Joseph Miller
Chief Financial Officer
Informative Buy
$9,740.00
a month ago
Huizinga Robert Bindert
Ex Vice President Of Research
Informative Buy
$120,800.00
a month ago
Recent AUPH News
- Aurinia to Participate in Upcoming Investor Healthcare Conferences • Business Wire • 07/02/2024 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 09:25:28 PM
- Aurinia Announces 2024 Annual General Meeting Results • Business Wire • 06/14/2024 04:16:00 PM
- Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024 • Business Wire • 06/05/2024 10:00:00 AM
- Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce • Business Wire • 06/04/2024 09:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/04/2024 09:25:39 PM
- Aurinia Provides Update on Proxy Statement • Business Wire • 06/03/2024 10:30:00 PM
- Aurinia Will Attend 2024 Jefferies Global Healthcare Conference • Business Wire • 05/30/2024 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:16:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:14:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:11:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:09:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:07:15 PM
- Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024 • Business Wire • 05/14/2024 10:00:00 AM
- Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024 • Business Wire • 05/09/2024 10:00:00 AM
- Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference • Business Wire • 05/07/2024 10:00:00 AM
- Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results • Business Wire • 05/02/2024 10:00:00 AM
- Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month • Business Wire • 05/01/2024 10:00:00 AM
- The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program • Business Wire • 04/30/2024 10:00:00 AM
- New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference • Business Wire • 04/16/2024 02:48:00 PM
- Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024 • Business Wire • 04/15/2024 10:00:00 AM
- Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference • Business Wire • 04/09/2024 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:44:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:43:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:42:46 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM